A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype

被引:28
作者
Chida, M
Yokoi, T
Nemoto, N
Inaba, M
Kinoshita, M
Kamataki, T
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Div Pharmacobiodynam,Kita Ku, Sapporo, Hokkaido 0600812, Japan
[2] Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Toxicol, Toyama, Japan
[3] Otsuka Pharmaceut Co Ltd, Tokushima 77101, Japan
[4] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan
来源
PHARMACOGENETICS | 1999年 / 9卷 / 03期
关键词
CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*18; genotype;
D O I
10.1097/00008571-199906000-00003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Two poor metabolizer individuals of debrisoquine were identified among 215 healthy Japanese by a phenotyping test, Analysis of the CYP2D6 gene from one of two poor metabolizers, who was not homozygous for the previously described CYP2D6 Variant alleles (CYP2D6*3, CYP2D6*4, CYP2D6*5 and CYP2D6*18), showed that this individual was heterozygous for a new allele, CYP2D6/C8 (CYP2D6*21), CYP2D6*21 I had a single cytosine insertion at position 2661 in exon 5, This cytosine insertion generated a stop codon at the 17 bp downstream of this insertion site, A method to detect this allele was established with an allele specific-polymerase chain reaction, This method showed that another one of two poor metabolizers also possessed CYP2D6*21 allele heterozygously, In 318 healthy Japanese, five individuals carried this allele, heterozygously (0.81%, 5/636 chromosomes), Based on the present and our previous data, the poor metabolizer frequency in Japanese was estimated to be 0.39%, which accounted for approximately 45% of the individuals phenotyped as poor metabolizers by in-vivo tests. Pharmacogenetics 9:287-293 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 33 条
  • [1] A NONSENSE MUTATION IN THE CYTOCHROME-P450 CYP2D6 GENE IDENTIFIED IN A CAUCASIAN WITH AN ENZYME DEFICIENCY
    BROLY, F
    MAREZ, D
    LOGUIDICE, JM
    SABBAGH, N
    LEGRAND, M
    BOONE, P
    MEYER, UA
    [J]. HUMAN GENETICS, 1995, 96 (05) : 601 - 603
  • [2] DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION
    BROLY, F
    GAEDIGK, A
    HEIM, M
    EICHELBAUM, M
    MORIKE, K
    MEYER, UA
    [J]. DNA AND CELL BIOLOGY, 1991, 10 (08) : 545 - 558
  • [3] CHIDA M, 1999, IN PRESS PHARMACOGEN
  • [4] GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS
    DAHL, ML
    YUE, QY
    ROH, HK
    JOHANSSON, I
    SAWE, J
    SJOQVIST, F
    BERTILSSON, L
    [J]. PHARMACOGENETICS, 1995, 5 (03): : 159 - 164
  • [5] ANALYSIS OF THE CYP2D6 GENE IN RELATION TO DEBRISOQUIN AND DESIPRAMINE HYDROXYLATION IN A SWEDISH POPULATION
    DAHL, ML
    JOHANSSON, I
    PALMERTZ, MP
    INGELMANSUNDBERG, M
    SJOQVIST, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (01) : 12 - 17
  • [6] Nomenclature for human CYP2D6 alleles
    Daly, AK
    Brockmoller, J
    Broly, F
    Eichelbaum, M
    Evans, WE
    Gonzalez, FJ
    Huang, JD
    Idle, JR
    IngelmanSundberg, M
    Ishizaki, T
    JacqzAigrain, E
    Meyer, UA
    Nebert, DW
    Steen, VM
    Wolf, CR
    Zanger, UM
    [J]. PHARMACOGENETICS, 1996, 6 (03): : 193 - 201
  • [7] THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS
    EICHELBAUM, M
    GROSS, AS
    [J]. PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) : 377 - 394
  • [8] DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT
    EICHELBAUM, M
    SPANNBRUCKER, N
    STEINCKE, B
    DENGLER, HJ
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) : 183 - 187
  • [9] A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION
    EVANS, DAP
    MAHGOUB, A
    SLOAN, TP
    IDLE, JR
    SMITH, RL
    [J]. JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) : 102 - 105
  • [10] EVERT B, 1994, N-S ARCH PHARMACOL, V350, P434